Preimplantation Genetic Screening (PGS) involves examining the chromosomal structure of an embryo to check for any genetic abnormalities. This test, in particular, involves performing a biopsy on the 5th day after fertilization on six embryos. This is usually conducted when a moderate number of viable embryos have been produced during an In Vitro Fertilization (IVF) cycle.
PGS aims to enhance the chances of a successful pregnancy and decrease the risk of miscarriage by only transferring chromosomally normal embryos into the uterus. PGS is often recommended for couples who have a history of genetic disorders, recurrent miscarriages, failed IVF cycles, or advanced maternal age.
The primary aim of PGS testing is to detect chromosomal abnormalities in embryos before they are implanted into the uterus. By doing so, the chances of a successful pregnancy can be significantly increased and the risk of miscarriage can be considerably reduced.
The test is conducted by an embryologist in a laboratory setting. On the 5th day of embryo development, a small number of cells are carefully extracted from each embryo. These cells are then examined for chromosomal abnormalities.
PGS testing may be considered by anyone undergoing IVF treatment, especially those with a history of recurrent miscarriages, failed IVF cycles, genetic disorders, or advanced maternal age. However, the decision to undertake PGS testing should be discussed thoroughly with a fertility specialist.
A chromosomally normal (or euploid) embryo is one that has the correct number of chromosomes - 46 in total, 23 from the egg and 23 from the sperm. Embryos with the correct number of chromosomes are more likely to develop into a successful pregnancy and a healthy baby.
If an abnormality is detected, that particular embryo is not chosen for implantation. The decision to proceed with the implantation of any remaining normal embryos would be made in discussion with your fertility specialist.
Yes, as PGS testing involves the examination of chromosomes, it can identify the gender of the embryos. However, the main aim of PGS testing is to identify chromosomally normal embryos, not to select the sex of the baby.
The results of PGS testing are generally available within 7-10 days. During this waiting period, the embryos are safely cryopreserved (frozen) until the results are ready.
PGS testing is a highly reliable method for detecting chromosomal abnormalities. However, like all tests, it's not 100% accurate and there is a small chance of a false positive or false negative result.
The process of biopsy involves the removal of a few cells from each embryo, which usually does not harm the embryos. However, the procedure should be performed by a skilled embryologist to minimize any potential risks.
The main risk associated with PGS testing is the potential for damage to the embryos during the biopsy process. However, this risk is minimal when the procedure is performed by a skilled embryologist.
While PGS testing can significantly increase the chances of a successful pregnancy by ensuring only chromosomally normal embryos are transferred, it does not guarantee a pregnancy. Other factors, such as the health and age of the woman, also play important roles.
PGS testing can identify a wide range of chromosomal abnormalities, but it cannot detect all genetic disorders. Some genetic disorders are caused by single gene mutations that are not detectable by PGS testing.
Yes, PGS testing can be performed on frozen embryos. The embryos would be thawed, biopsied, and then refrozen until the results are available.
No, PGS testing itself does not increase the chance of having twins or multiples. However, the transfer of multiple embryos can increase the chance of a multiple pregnancy.
While both PGS and PGD involve genetic testing of embryos, they are used for different purposes. PGS is used to screen for chromosomal abnormalities in embryos, while PGD is used to identify specific genetic disorders in embryos when one or both parents are known to be carriers of the disorder.